# ACCURAY INC (ARAY) — capital_raise [completed]
Source: SEC API (secapi.ai) · situation sit_783d3157c5f6f4b89cd0 · retrieved 2026-08-11T16:03:51.108Z

## Overview
Accuray Incorporated develops and sells radiation therapy and radiosurgery systems for cancer treatment, including its CyberKnife and TomoTherapy platforms.

On July 29, 2026, Accuray Incorporated entered into a Securities Purchase Agreement with existing investors to issue 55,000 shares of Series A Convertible Preferred Stock for an aggregate purchase price of $55.0 million ($1,000 per share). The consideration consists of $15.0 million in cash and $40.0 million of existing indebtedness conversion. The Series A Preferred Stock is convertible into Common Stock at an initial conversion price of approximately $0.50 per share, accrues dividends at 8% per annum, and has a liquidation preference equal to the greater of $1,000 per share plus unpaid dividends or the amount holders would receive if converted immediately prior to liquidation. Concurrently, the Company issued warrants to purchase approximately 15.3 million shares of Common Stock at $0.01 per share, exercisable for 7 years. Effective upon closing, outstanding warrants to purchase approximately 27.6 million shares (consisting of June 2025 Premium Warrants at $1.68, December 2025 Super Premium Warrants at $1.50, and December 2025 Premium Warrants at $1.25) will be automatically cancelled and extinguished. The closing is subject to stockholder approval and implementation of a reverse stock split at a ratio between 1-for-15 and 1-for-40.

## Terms
- Counterparty: TCW Asset Management Company LLC and other existing investors · Deal value: $55.0M · Consideration: mixed · Price/share: $1000

## Key dates
- Completed 2026-07-29

## Timeline
- 2026-07-29 · 8-K (0001437749-26-024904): 8-K - ACCURAY INC — *Accuray Incorporated develops and sells radiation therapy and radiosurgery systems for cancer treatment, including its CyberKnife and TomoTherapy platforms.* On July 29, 2026, Accuray Incorporated entered into a Securities Purchase Agreement with existing investors to issue 55,000 shares of Series A Convertible Preferred Stock for an aggregate purchase price of $55.0 million ($1,000 per share). The consideration consists of $15.0 million in cash and $40.0 million of existing indebtedness conversion. The Series A Preferred Stock is convertible into Common Stock at an initial conversion price of approximately $0.50 per share, accrues dividends at 8% per annum, and has a liquidation preference equal to the greater of $1,000 per share plus unpaid dividends or the amount holders would receive if converted immediately prior to liquidation. Concurrently, the Company issued warrants to purchase approximately 15.3 million shares of Common Stock at $0.01 per share, exercisable for 7 years. Effective upon closing, outstanding warrants to purchase approximately 27.6 million shares (consisting of June 2025 Premium Warrants at $1.68, December 2025 Super Premium Warrants at $1.50, and December 2025 Premium Warrants at $1.25) will be automatically cancelled and extinguished. The closing is subject to stockholder approval and implementation of a reverse stock split at a ratio between 1-for-15 and 1-for-40.
  https://www.sec.gov/Archives/edgar/data/1138723/0001437749-26-024904.txt

## Citations
- 0001437749-26-024904 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000143774926024904